Location History:
- Karnataka Bangalore, IN (2022)
- Bengaluru, IN (2022 - 2023)
Company Filing History:
Years Active: 2022-2023
Title: Veeresha Kamanagowda: Innovator in Antibody Technology
Introduction
Veeresha Kamanagowda is a prominent inventor based in Bengaluru, India. He has made significant contributions to the field of biotechnology, particularly in the development of innovative methods for antibody generation and expression.
Latest Patents
Kamanagowda holds four patents, with his latest innovations focusing on vectors for cloning and expressing proteins. One of his notable patents describes vectors that facilitate the cloning and expression of genetic material, including antibody genes. These vectors are designed to express antibody genes in various formats, such as Fab or scFv, utilizing phage display technology for efficient screening and identification of lead molecules against antigens. Another patent outlines a method for generating a human naïve antibody library, which encompasses a diverse pool of nucleic acid sequences derived from natural antibody repertoires. This method employs a combination of phage and yeast antibody surface display concepts, allowing for the screening of large antibody library sizes and enhancing the folding of antibody structures.
Career Highlights
Veeresha Kamanagowda is currently associated with Zumutor Biologics Inc., where he continues to push the boundaries of antibody technology. His work has been instrumental in advancing the understanding and application of antibody engineering.
Collaborations
Kamanagowda collaborates with talented professionals in his field, including Sohang Chatterjee and Kavitha Iyer Rodrigues. Their combined expertise contributes to the innovative projects at Zumutor Biologics Inc.
Conclusion
Veeresha Kamanagowda is a key figure in the biotechnology sector, with a focus on antibody technology and innovative methods for protein expression. His contributions are paving the way for advancements in therapeutic applications and antibody development.